<DOC>
	<DOCNO>NCT01405742</DOCNO>
	<brief_summary>The purpose pilot R34 trial determine feasibility large single dose Phase III study hemophilia adult prophylaxis compare weekly thrice-weekly recombinant factor VIII . Efficacy measure bleeding frequency , factor usage , joint range motion , cost , quality-of-life , F.VIII level , inter-dose hypocoagulability thrombin generation . Safety measure inhibitor formation bleed event unresponsive two rescue dos .</brief_summary>
	<brief_title>Hemophilia Adult Prophylaxis Study : Factor VIII Severe Hemophilia A</brief_title>
	<detailed_description>The purpose 52-week pilot R34 randomize , open-label , non-inferiority , cross-over study determine feasibility large single dose Phase III study hemophilia adult prophylaxis . The primary efficacy endpoint bleeding frequency . Secondary endpoint include factor usage , joint range motion , cost , quality-of-life , inter-dose hypocoagulability thrombin generation time F.VIII activity also determine . Safety measure frequency bleed unresponsive two rescue treatment . Inhibitor formation anti-F.VIII Bethesda assay , clinical frequency thrombosis allergic reaction also assess . Subject acceptance adherence treatment intervention determine ; web-based data entry case report form , digital range-of-motion image , quality-of-life instrument implement . The relation bleeding frequency relative inter-dose hypocoagulability , assess inter-dose thrombin generation time ( TGT ) , endogenous thrombin potential ( ETP ) , factor VIII level . Optimal blood sample collection ship method determine . For test , estimate determine completeness congruency , order determine adjustment revision require initiate large phase III Randomized clinical trial . All test exploratory , may determine test , approach realistic , estimate standard deviation future power analysis .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Adult males 18 year old Severe hemophilia A ( F.VIII &lt; 0.01 U/ml ) At least 150 exposure day F.VIII product No detectable inhibitor No history allergic reaction Platelets least 150,000/ul If HIV ( + ) , CD4 least 200/ul , HIVVL &lt; 48 copies/ml , cART compliant If HCV ( + ) , splenomegaly , varix , GI bleed , ascites , edema , encephalopathy Willingness comply crossover design , randomization schema Willingness keep personal diary bleeding frequency factor use Willingness make every 3 month visit , coagulation test wks 2 , 28 Acquired hemophilia Any bleed disorder hemophilia A Presence inhibitor factor VIII Historic platelet count &lt; 100,000 Use experimental drug Surgery anticipate next 52 week Symptomatic HCV ( splenomegaly , varix , GI bleed , ascites , edema , encephalopathy ) Symptomatic HIV ( CD4 &lt; 200/ul HIV VL 48 copy/ml , cART noncompliant ) Life expectancy le 5 year Investigational drug study within 4 week prior study Inability comply study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Recombinant factor VIII</keyword>
</DOC>